Warmuth Markus

President & CEO

Warmuth Markus has filed 7 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 7 of those filings fall inside the rolling window. Most recent filing: Jul 17, 2026.

On the most recent filing, Warmuth Markus is listed as President & CEO at Monte Rosa Therapeutics, Inc. Inside the rolling window, Warmuth Markus reported no open-market purchases and 7 open-market sales totaling $951K in GLUE. The largest disclosed transaction in the window is a sale of 9,500 GLUE shares on Jul 16, 2026, worth $220K.

Companies traded

Other insiders at GLUE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$951K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
GLUESale$220KJul 17SEC ↗
GLUESale$106KJun 2SEC ↗
GLUESale$103KMay 5SEC ↗
GLUESale$141KApr 15SEC ↗
GLUESale$98KMar 4SEC ↗
GLUESale$128KJan 9SEC ↗
GLUESale$154KJan 5SEC ↗
Showing 1–7 of 7
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Warmuth Markus made?

Warmuth Markus has filed 7 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.

Which companies does Warmuth Markus trade?

Warmuth Markus has filed SEC Form 4 disclosures for 1 company, including GLUE.

When was Warmuth Markus's most recent SEC Form 4 filing?

Warmuth Markus's most recent SEC Form 4 filing on Tracefour is dated Jul 17, 2026.

What is Warmuth Markus's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Warmuth Markus is listed as President & CEO.

What is Warmuth Markus's total buy and sell value in the current window?

Inside the rolling retention window, Warmuth Markus bought $0 and sold $951K based on SEC Form 4 filings.

What was Warmuth Markus's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 9,500 GLUE shares on 2026-07-16, worth $220K, per SEC Form 4 filings.